Unjha Formulations Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

Quality Assessment: Weakening Fundamentals Amid Operating Losses

Unjha Formulations continues to struggle with its core financial health, as evidenced by its flat results in the fourth quarter of FY25-26. The company reported an operating loss with PBDIT at a negative ₹0.45 crore and PBT less other income at ₹-0.49 crore, marking the lowest quarterly figures in recent periods. Earnings per share (EPS) also declined sharply to ₹-1.65, underscoring the lack of profitability.

Moreover, the company’s ability to service debt remains weak, with an average EBIT to interest ratio of just 0.49, indicating insufficient earnings to cover interest expenses comfortably. This poor coverage ratio raises concerns about financial stability and long-term sustainability. The weak long-term fundamental strength is a critical factor in the downgrade, signalling that the company is not generating adequate returns to justify a more favourable rating.

Valuation: Attractive but Insufficient to Offset Risks

Despite the negative operational performance, Unjha Formulations exhibits a very attractive valuation profile. The company’s return on equity (ROE) stands at a robust 18.5%, and it trades at a price-to-book (P/B) ratio of 2.3, which is considered reasonable within its sector. Additionally, the stock is currently priced at a discount relative to its peers’ historical valuations, suggesting potential value for long-term investors.

However, the valuation attractiveness is tempered by the company’s poor financial trend and technical outlook. While profits have risen by 31% over the past year, the stock price has declined by 18.03%, resulting in a low PEG ratio of 0.2. This divergence between earnings growth and share price performance indicates market scepticism about the company’s prospects, limiting the positive impact of valuation metrics on the overall rating.

Financial Trend: Flat Quarterly Performance and Underperformance

The financial trend for Unjha Formulations has been largely flat, with the latest quarter showing no significant improvement. The company’s operating losses and negative earnings highlight a lack of momentum in profitability. This stagnation is reflected in the stock’s market performance, which has underperformed the broader indices.

Over the past year, Unjha Formulations’ stock price declined by 18.03%, considerably worse than the BSE500 index’s negative return of 2.06%. This underperformance signals investor concerns about the company’s growth prospects and financial health. Although the company has demonstrated some long-term growth—delivering a 105.7% return over five years and 116.67% over ten years—the recent trend is decidedly negative, contributing to the downgrade.

Technical Analysis: Shift to Bearish Sentiment

The downgrade to Strong Sell is largely driven by a deterioration in technical indicators. The technical grade shifted from mildly bearish to outright bearish, reflecting increased downside risk. Key technical metrics reinforce this negative outlook:

• MACD readings on both weekly and monthly charts remain bearish, indicating sustained downward momentum.
• Moving averages on the daily timeframe are bearish, suggesting the stock is trading below key support levels.
• Bollinger Bands on weekly and monthly charts show mildly bearish signals, pointing to potential volatility and downward pressure.
• While the KST indicator shows a mildly bullish signal on the weekly chart, it remains bearish on the monthly, underscoring mixed but predominantly negative momentum.
• RSI and Dow Theory indicators currently show no clear trend, adding to the uncertainty but not offsetting the bearish signals.

The stock price remains near its 52-week low of ₹18.60, currently trading at ₹19.50, well below its 52-week high of ₹30.40. This price action confirms the technical weakness and supports the Strong Sell rating.

Market Capitalisation and Shareholding Structure

Unjha Formulations is classified as a micro-cap stock, which inherently carries higher volatility and risk compared to larger companies. The majority of its shares are held by non-institutional investors, which may contribute to lower liquidity and increased price fluctuations. This ownership structure, combined with the company’s weak financial and technical profile, further justifies the cautious stance adopted by analysts.

Comparative Performance and Outlook

When compared to the broader market and sector peers, Unjha Formulations’ recent performance is disappointing. While the Sensex and BSE500 indices have shown modest declines or flat returns over the past year, this stock’s sharper fall of over 18% highlights its relative weakness. Even though the company has delivered strong returns over longer horizons—55.38% over three years and 105.7% over five years—the current environment is unfavourable.

Given the combination of flat financial results, operating losses, poor debt servicing ability, and bearish technical indicators, the downgrade to a Strong Sell rating with a Mojo Score of 26.0 is a reflection of heightened risk. Investors are advised to exercise caution and consider alternative opportunities within the Pharmaceuticals & Biotechnology sector or other market segments.

Summary of Rating Change

The downgrade from Sell to Strong Sell on 1 June 2026 is primarily driven by the following four parameters:

• Quality: Weak long-term fundamentals with operating losses and poor EBIT to interest coverage ratio (0.49).
• Valuation: Attractive ROE of 18.5% and P/B of 2.3, but valuation benefits are overshadowed by financial and technical weaknesses.
• Financial Trend: Flat quarterly performance with negative EPS and underperformance relative to market indices.
• Technicals: Shift from mildly bearish to bearish trend with negative MACD, moving averages, and Bollinger Bands signals.

These factors collectively underpin the Strong Sell rating and suggest that Unjha Formulations Ltd is currently a high-risk investment within the pharmaceuticals micro-cap space.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →